Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
OceanPact agrees to sell two offshore support vessels for USD 86 million

OceanPact agrees to sell two offshore support vessels for USD 86 million

BitgetBitget2026/11/03 12:05
  • OceanPact subsidiaries agreed on November 2, 2026, to sell CBO Energy and CBO Wiser to a foreign offshore-support group.
  • The purchase price totals USD 86 million, or USD 43 million per vessel; a 10% deposit is due within 10 business days.
  • Closing is expected by December 18, 2026, when the remaining balance becomes payable.
  • Completion remains subject to both parties’ corporate approvals, consent from CBO Wiser’s client and other required authorizations.
  • CBO Wiser must be bareboat-chartered to subsidiary CBO for its existing client contract’s remaining term, preserving current operating terms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oceanpact Servicos Maritimos SA published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss